Search Results for:
ACRO AI/ML Committee Releases Principles for Responsible AI
WASHINGTON–Representing clinical research organizations (CROs) and clinical technology companies actively engaged in developing and deploying AI tools to support and improve drug development functions, ACRO is pleased to announce the release of ACRO’s Principles for Responsible AI. Drafted by a team of CRO and technology subject matter experts, the ACRO Principles articulate an approach to the
ACRO AI/ML Committee Releases Principles for Responsible AI Read More »
ACRO Artificial Intelligence & Machine Learning Principles Statement
ACRO’s Artificial Intelligence/Machine Learning Committee produced the following Principles Statement in December 2023. The committee represents the industry to regulators and policymakers considering regulation and legislation that could impact the use of AI/ML in drug development.
ACRO Artificial Intelligence & Machine Learning Principles Statement Read More »
How much do you know about Risk-Based Monitoring (RBM)
Risk based monitoring is an adaptive approach that directs monitoring focus and activities to the evolving areas of greatest need which have the most potential to impact patient safety and data quality. How much do you know about Risk-Based Monitoring (RBM)? This webinar series from ACRO’s CRO Forum and The Society for Clinical Research Sites (SCRS) aims to educate
How much do you know about Risk-Based Monitoring (RBM) Read More »
Decentralizing Clinical Trials: The White Paper
ACRO DCT White Paper: A New Quality-by-Design, Risk-Based Framework ACRO’s DCT White Paper provides an overview of considerations for decentralized clinical trials and introduces the Quality-by-Design Manual and Risk-Assessment Template.
Decentralizing Clinical Trials: The White Paper Read More »
Sandy Kennedy
Cassandra Strickland Kennedy has served as Chief Quality, Regulatory Affairs, and Sustainability Officer since May 2023 with oversight of Global Regulatory Compliance, Quality Assurance and Environmental, Social and Governance at Fortrea. Sandy brings more than three decades of biopharmaceutical industry experience, with a long track record of success in leadership positions within the pharmaceutical and
Risk-based Monitoring in Clinical Trials: Past, Present & Future
ACRO’s RBQM report shows how clinical trials were forced to shift to remote monitoring during the COVID-19 pandemic, and highlights why the industry shouldn’t turn back. Risk-based monitoring (RBM) is a powerful tool for efficiently ensuring patient safety and data integrity in a clinical trial, enhancing overall trial quality. To better understand the RBM implementation
Risk-based Monitoring in Clinical Trials: Past, Present & Future Read More »